SOURCES SOUGHT
R -- Detection Assay Systems - Sources Sought - 4607516
- Notice Date
- 8/9/2017
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SS-17-427
- Archive Date
- 8/29/2017
- Point of Contact
- Danielle R. Brown, Phone: 301 480 2385
- E-Mail Address
-
danielle.brown2@nih.gov
(danielle.brown2@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Sources Sought - 4607516 - Detection Assay Systems Federal Business Opportunities (FBO) SOURCES SOUGHT NOTICE 1.Solicitation Number: HHS-NIH-NIDA-SSSA-SS-17-427 2.Title: Detection Assay Systems 3.NAICS Code: 325414 - Biological Product (Except Diagnostic) Manufacturing 4.Description: This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: Tox21 collaboration between NCATS (then NCGC), NTP, EPA and FDA started off with an aim to screen tens and thousands of known drugs and compounds in vitro by reducing the cost and time consuming processes involved in traditional toxiciticy testing methods. Since its inception nearly a decade ago, several screenings against Tox21 compound collection were performed at NCATS by running cell based assays that are focusing mainly on different targets and toxicity pathways which include nuclear receptor signaling, stress response, developmental toxicology, GPCR/cAMP signaling, and Epigentics etc. All these assays used either luciferase or fluorescence reporter gene technology for readouts. In order to quantify the induction/inhibition of these reporter gene activities, different detection assay systems have been used. Purpose and Objectives: The purpose of this requirement is to procure mice testing services to test compound alone and in combination with topotecan in CB.17 SCID mice to determine if the compound can reduce leukemia tumor size. Delivery Schedule: Within 30 days after receipt of order (ARO) Project Requirements: Luciferase Assay System: •High-throughput, sensitive quantitation of firefly luciferase activity in mammalian cell culture. •Reagent consist of two components, a Luciferase Reagent Buffer and Luciferase Reagent Substrate. •Assay must contain: oHighly sensitive detection of firefly luciferase activity. oThe signal output must be stable for more than two hours, providing flexibility with regard to incubation time. oSimple one-step, homogeneous protocol. oOne-step homogeneous protocol must minimize hanlding steps to support high-throughput screening applications. oMust work well with a variety of common media containin -10% serum and phenol red. oDoes not require a luminometer with injectors. Cell Viability Assay System: •Quantifies the protease activity within live cells. •Reagent is nonlytic, and is a single-reagent-addition fluorescence assay. •Assay is homogeneous and stable. •The assay can be multiplexed with the luciferase assay for measuring viability. 3/7 Assay System: •Measures the apoptosis for cell based methods. •A luminescent assay for measuring Caspase-3/7 activities. •The assay is homogeneous and highly reproducible. •Assay is designed for use with multiwell plate formats. Annexin Apoptosis Assay: •Measures the apoptosis and necrosis for cell based methods. •Assay is homogeneous and bioluminescent. •The method obviates laborious washing and sample preparation steps associated with traditional annexin methods. •Fully compatible with either plate-based multimodal signal detection or bioluminescent imaging systems. •The reagent contains a novel time-released luciferase substrate and a cell impermeable, fluorogenic DNA dye for monitoring cell membrane integrity. Luminescent Cell Viability Assay System: •Quantifies the ATP present in the cell. •Assay is homogeneous. •Designed for use with multi-well formats, and so ideal for automated high-throughput screenings. •The assay is very stable for a number of thaw and freeze cycles. •The signal generated after adding this reagent is stable for at least 5hrs, and this extended half-life provides flexibility for processing of multiple plates in high throughput screenings. Quantity: Fifty-one (51) total Detection Assay Systems Capability statement /information sought. Please provide a capability statement, this includes: •Provide evidence the respondent has performed services. •Provide evidence of similar previous contracts of research of the same magnitude. •Information regarding (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed project of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. Please provide your DUNS number, organization name, address point of contact, and size and type of business (e.g., 8(a), HubZone, etc.,) pursuant to the applicable NAICS code and any other information that may be helpful. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. The response is limited to one to two (1-2) page limit. The 1-2 page(s) do not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Danielle R. Brown, Contract Specialist, at Danielle.brown2@nih.gov. The response must be received on or before Monday, August 14, 2017 at 12:00PM, Eastern Standard Time. "Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-SS-17-427/listing.html)
- Place of Performance
- Address: 9800 Medical Drive Building B, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN04619690-W 20170811/170809231728-9e9e15a9fad95d9cf5ec70cd8f5f29d8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |